Entrada Begin Period Cash Flow from 2010 to 2024
| TRDA Stock | USD 18.80 0.75 4.16% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 49.1 M | Current Value 93.3 M | Quarterly Volatility 68.6 M |
Check Entrada Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entrada Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.5 M, Interest Income of 16 M or Depreciation And Amortization of 3 M, as well as many indicators such as Price To Sales Ratio of 3.1, Dividend Yield of 0.0 or PTB Ratio of 2.16. Entrada financial statements analysis is a perfect complement when working with Entrada Therapeutics Valuation or Volatility modules.
Entrada | Begin Period Cash Flow |
Latest Entrada Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Entrada Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Entrada Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entrada Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Entrada Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 51,451,689 | |
| Geometric Mean | 36,595,531 | |
| Coefficient Of Variation | 133.36 | |
| Mean Deviation | 37,534,128 | |
| Median | 28,237,000 | |
| Standard Deviation | 68,616,674 | |
| Sample Variance | 4708.2T | |
| Range | 274.2M | |
| R-Value | 0.44 | |
| Mean Square Error | 4074.3T | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | 6,800,594 | |
| Total Sum of Squares | 65915.5T |
Entrada Begin Period Cash Flow History
About Entrada Therapeutics Financial Statements
Entrada Therapeutics stakeholders use historical fundamental indicators, such as Entrada Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Entrada Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Entrada Therapeutics' assets and liabilities are reflected in the revenues and expenses on Entrada Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Entrada Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 49.1 M | 93.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out the analysis of Entrada Therapeutics Correlation against competitors. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.